Arbutus Biopharma Corp
ABUS
NASDAQ
Biotechnology
$4.67
USD
+0.09 (+1.97%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $901.76M
Volume 1.4M
Revenue
$181.72M
TTM
+1078.8%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$153.05M
TTM
+382.1%
YoY
Operating Cash Flow
$-24.63M
TTM
+59.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 10.7 | 0.5 | 1.1 | 179.1 | 1.0 |
YoY Growth | +522.2% | -60.5% | -33.2% | +10054.5% | -90.6% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 10.7 | 0.5 | 1.1 | 179.1 | 1.0 |
Selling, General & Administrative | 3.3 | 3.0 | 3.7 | 5.9 | 3.9 |
Other Operating Expenses | 0.4 | 0.4 | -2.4 | 0.2 | 0.2 |
Total Operating Expenses | 9.3 | 9.2 | 6.3 | 10.2 | 7.0 |
Operating Income | 1.5 | -8.7 | -5.3 | 168.9 | -6.0 |
EBITDA | 1.7 | -8.6 | -5.0 | 168.9 | -6.0 |
Other Income / Expense | 0.0 | -0.0 | 0.7 | -0.0 | -0.1 |
Total Other Income / Expense | 1.0 | 0.9 | 1.5 | 0.8 | 0.8 |
Income Before Income Taxes | 2.5 | -7.7 | -3.8 | 169.7 | -5.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | 2.5 | -7.7 | -3.8 | 169.7 | -5.1 |
Consolidated Net Income / Loss | 2.5 | -7.7 | -3.8 | 169.7 | -5.2 |
Net Income Attributable to Common Shareholders | 2.5 | -7.7 | -3.8 | 169.7 | -5.2 |
Basic EPS | $0.01 | -$0.04 | -$0.02 | $0.88 | -$0.03 |
Diluted EPS | $0.01 | -$0.04 | -$0.02 | $0.87 | -$0.03 |
Basic Shares Outstanding | 191.6M | 191.8M | 192.4M | 193.8M | 197.5M |
Diluted Shares Outstanding | 192.4M | 191.8M | 191.5M | 195.2M | 197.5M |